Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
CWBR CohBar Inc
TSLA Tesla Inc
WEC WEC Energy Group Inc
PFE Pfizer Inc
T AT&T Inc
BFC Bank First Corp
RIGMF Ridgestone Mining Inc
BAC Bank of America Corp
WFC Wells Fargo & Co
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Closing Price
$76.35
Day's Change
0.29 (0.38%)
Bid
--
Ask
--
B/A Size
--
Day's High
77.09
Day's Low
75.65
Volume
(Light)
Volume:
6,380,965

10-day average volume:
8,980,811
6,380,965

Boeing to benefit from 'recovery' in passenger air travel

11:13 am ET June 9, 2020 (MarketWatch)
Print

Boeing Co.'s (BA) "fate" is tied to the improving outlook for passenger traffic and there has been some signs of recovery in the industry, analysts at Benchmark said in a note Tuesday. They raised their price target on Boeing stock to $260 from $180, implying a 15% upside over Tuesday's stock price. "Continued anemic passenger traffic will certainly lead to an acceleration of aircraft cancellations," the analysts said. Fortunately for Boeing, the most recent data, including IATA calling April the bottom of COVID-19 air traffic crunch, American Airlines Group Inc. (AAL) increasing domestic capacity for July, and recent TSA foot traffic numbers "are all suggestive of increasing passenger confidence," the analysts said. They reiterated their buy rating on the shares. Boeing stock has declined 31% this year, compared with losses of 0.6% and 4% for the S&P 500 index and the Dow Jones Industrial Average .

-Claudia Assis; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

June 09, 2020 11:13 ET (15:13 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.